{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-33.0","upperLimit":"20.4","value":"-3.2"},{"groupId":"OG001","lowerLimit":"-15.4","upperLimit":"29.7","value":"7.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"description":"Assessed by using the serum-protein electrophoresis","dispersionType":"Full Range","groups":[{"description":"Randomly assigned participants receive a stepped dose escalation until target daily dose of 1500mg Metformin XR is reached (3 x 500mg pills/day). The intervention duration will last an additional 6 months.\n\nMetformin Extension:\n\nParticipants will have the option of unblinding at the end of their 6months treatment and those who were randomly assigned to the metformin experimental arm can continue taking metformin if they opt in. The extended intervention duration will last an additional 6 months. (1500mg Metformin XR or highest tolerated dose )\n\nMetformin XR: Orally by mouth","id":"OG000","title":"Metformin"},{"description":"Randomly assigned participants receive a stepped dose escalation until target daily dose of 3 pills/day is reached. The intervention duration will last 6 months.\n\nPlacebo: Orally by mouth","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"8 participants in the metformin arm and 6 participants in the control arm did not have analyzable m-protein data.","reportingStatus":"POSTED","timeFrame":"Baseline to 6-months","title":"(M-)Protein Concentrations Change","type":"PRIMARY","unitOfMeasure":"percent change"}